proxyvotesnow.com

Home › Companies › BridgeBio Pharma, Inc. › 2025-2026

BridgeBio Pharma, Inc. 2025-2026 Proxy Voting Records

Compiled from SEC Form N-PX filings and BridgeBio Pharma, Inc.’s Form 8-K, filed 2026-06-26 (Item 5.07 on EDGAR). Page generated 02 October 2026.

  • 20Reported items
  • 466Asset managers
  • 4,364Fund votes
  • 2026-06-22Meeting date

Proxy season: 2023-2024 2024-2025 2025-2026

Explore BridgeBio Pharma, Inc. in the interactive database Compare manager voting policies

Official 2025-2026 meeting results reported by BridgeBio Pharma, Inc.

These tallies are BridgeBio Pharma, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2026-06-26 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

BridgeBio Pharma, Inc. — official shareholder meeting results, meeting held 2026-06-22
Ballot itemForAgainst AbstainWithheldBroker non-votesOutcome
Elect Director: James C. Momtazee 156,790,852---- 4,316,018-- Majority: yes
Elect Director: Frank P. McCormick, Ph.D. 153,020,532---- 8,086,338-- Majority: yes
Elect Director: Hannah A. Valantine, M.D. 129,081,930---- 32,024,940-- Majority: yes

Source: BridgeBio Pharma, Inc., Form 8-K, filed with the SEC on 2026-06-26 — read the filing on EDGAR.

How asset managers voted at the BridgeBio Pharma, Inc. 2025-2026 meeting

Each item below shows how the 466 asset managers that disclosed a BridgeBio Pharma, Inc. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of BridgeBio Pharma, Inc.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.

1. To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the proxy statement.

SECTION 14A SAY-ON-PAY VOTES

Combines 5 wordings of this item as funds reported it.

94% fund support · no official result

FOR 94%

The 441 asset managers below cast 94% of the shares they voted on this item FOR (174,857,590 for, 10,235,046 against).

FOR: 174,857,590 (94.1%)AGAINST: 10,235,046 (5.5%)ABSTAIN: 40,813 (0.0%)SPLIT: 664,940 (0.4%)NOT VOTED: 1,530 (0.0%)
Largest asset managers voting on “To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in ” at BridgeBio Pharma, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard18,509,65410 40For
Janus Henderson18,435,1960 00For
Kohlberg Kravis Roberts & Co. L.P.13,260,9710 00For
VIKING GLOBAL INVESTORS LP11,763,1750 00For
BlackRock11,435,964373 00For
Fidelity8,615,12288 00For
Invesco31,9067,135,583 00Against
T. Rowe Price6,272,0990 00For
FARALLON CAPITAL MANAGEMENT, L.L.C.5,740,6390 00For
JANUS INVESTMENT FUND5,303,7190 00For
Aisling Capital Management LP5,089,6110 00For
GEODE CAPITAL MANAGEMENT, LLC4,844,0820 00For
Polar Capital Holdings Plc4,789,4220 00For
Charles Schwab3,967,4290 00For
State Street3,369,2230 00For
AllianceBernstein2,298,1370 00For
John Hancock2,223,1300 00For
FRANKLIN ADVISERS INC1,853,7630 00For
American Century1,760,8940 00For
Wellington1,734,5540 00For
Allspring1,474,9150 00For
NOMURA INVESTMENT MANAGEMENT BUSINESS TRUST1,292,1970 00For
PICTET ASSET MANAGEMENT SA1,241,5720 00For
Hood River Capital Management LLC1,140,4330 00For
Delaware/Macquarie1,134,6520 00For

Showing the 25 largest of 441 asset managers. See all 441 in the interactive database.

2. To conduct a non-binding advisory vote on the frequency of future non-binding advisory votes to approve the compensation of the Company's named executive officers.

SECTION 14A SAY-ON-PAY VOTES

Combines 4 wordings of this item as funds reported it.

100% fund support · no official result

ONE YEAR 76%1 YEAR 17%

The 441 asset managers below cast 100% of the shares they voted on this item FOR (6,121,736 for, 0 against).

FOR: 6,121,736 (3.3%)ABSTAIN: 40,809 (0.0%)ONE YEAR: 141,534,908 (76.1%)1 YEAR: 30,914,549 (16.6%)2 YEARS: 5,089,811 (2.7%)3 YEARS: 925,727 (0.5%)1YR: 763,702 (0.4%)THREE YEARS: 447,599 (0.2%)3: 29,289 (0.0%)1-YEAR: 28,961 (0.0%)NOT VOTED: 1,530 (0.0%)1.0: 385 (0.0%)TWO YEARS: 32 (0.0%)2.0: 15 (0.0%)3.0: 4 (0.0%)
Largest asset managers voting on “To conduct a non-binding advisory vote on the frequency of future non-binding advisory votes to approve the co” at BridgeBio Pharma, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard00 00One Year
Janus Henderson00 00One Year
Kohlberg Kravis Roberts & Co. L.P.00 00One Year
VIKING GLOBAL INVESTORS LP00 00One Year
BlackRock00 001 Year
Fidelity00 00One Year
Invesco00 00One Year
T. Rowe Price00 00One Year
FARALLON CAPITAL MANAGEMENT, L.L.C.5,740,6390 00For
JANUS INVESTMENT FUND00 00One Year
Aisling Capital Management LP00 002 Years
GEODE CAPITAL MANAGEMENT, LLC00 00One Year
Polar Capital Holdings Plc00 00One Year
Charles Schwab00 001 Year
State Street00 00One Year
AllianceBernstein00 00One Year
John Hancock00 00One Year
FRANKLIN ADVISERS INC00 00One Year
American Century00 00One Year
Wellington00 001 Year
Allspring00 00One Year
NOMURA INVESTMENT MANAGEMENT BUSINESS TRUST00 00One Year
PICTET ASSET MANAGEMENT SA00 00One Year
Hood River Capital Management LLC00 001 Year
Delaware/Macquarie00 00One Year

Showing the 25 largest of 441 asset managers. See all 441 in the interactive database.

3. To approve an amendment and restatement of the 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan to increase the number of shares of common stock reserved for issuance thereunder by 2,000,000 shares.

COMPENSATION

85% fund support · no official result

FOR 85%AGAINST 15%

The 124 asset managers below cast 85% of the shares they voted on this item FOR (54,691,773 for, 9,401,361 against).

FOR: 54,691,773 (85.0%)AGAINST: 9,401,361 (14.6%)ABSTAIN: 272,209 (0.4%)NOT VOTED: 204 (0.0%)
Largest asset managers voting on “To approve an amendment and restatement of the 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option a” at BridgeBio Pharma, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard16,996,25579,002 40For
Fidelity6,214,18560,100 00For
BlackRock6,202,8580 00For
JANUS INVESTMENT FUND3,914,1051,389,614 00For
Invesco3,054,1070 00For
T. Rowe Price2,714,0680 00For
Charles Schwab1,969,8570 00For
Delaware/Macquarie01,134,652 00Against
Columbia Threadneedle1,052,5230 00For
Lord Abbett942,1450 00For
American Century0831,114 00Against
JPMorgan809,8540 00For
Capital Group0763,702 00Against
Principal257,703458,236 00Against
Manager Directed Portfolios708,4000 00For
Franklin Custodian Funds700,0000 00For
Jackson National639,13943,514 00For
Allspring0649,905 00Against
FRANKLIN STRATEGIC SERIES637,8080 00For
Equitable630,6300 00For
AllianceBernstein574,1830 00For
PRIMECAP Odyssey Funds479,0800 00For
TIAA446,0860 00For
Legg Mason436,5575,985 00For
MUTUAL FUND SERIES TRUST437,1300 00For

Showing the 25 largest of 124 asset managers. See all 124 in the interactive database.

4. To elect three (3) nominees for director, James C. Momtazee, Frank P. McCormick, Ph.D., and Hannah A. Valantine, M.D., to serve as Class I directors to hold office until the date of the annual meeting of stockholders following the year ending December 31, 2028 and until their successors are duly elected and qualified: Frank P. McCormick, Ph.D.

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 9 wordings of this item as funds reported it.

95% Majority: yes · of votes cast

FOR 95%
FOR: 153,020,532WITHHELD: 8,086,338

BridgeBio Pharma, Inc.’s own tally for this item (“Elect Director: Frank P. McCormick, Ph.D.”): 153,020,532 for, 8,086,338 withheld, per its Form 8-K filed 2026-06-26 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 195,707,702 outstanding shares: 78% for, 4% withheld (82% of the company cast a for/withheld vote).

The 123 asset managers below cast 100% of the shares they voted on this item FOR (61,342,754 for, 0 against).

FOR 95%
FOR: 61,342,754 (95.0%)ABSTAIN: 3,232,112 (5.0%)NOT VOTED: 204 (0.0%)
Largest asset managers voting on “To elect three (3) nominees for director, James C. Momtazee, Frank P. McCormick, Ph.D., and Hannah A. Valantin” at BridgeBio Pharma, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard17,065,8530 9,4070For
Fidelity6,274,2850 00For
BlackRock6,202,8580 00For
JANUS INVESTMENT FUND5,303,7190 00For
Invesco3,054,1070 00For
T. Rowe Price2,714,0680 00For
Charles Schwab1,969,4100 4470For
Delaware/Macquarie1,134,6520 00For
Columbia Threadneedle1,052,5230 00For
Lord Abbett942,1450 00For
American Century831,1140 00For
JPMorgan809,8540 00For
Capital Group763,7020 00For
Principal458,2360 257,7030For
Manager Directed Portfolios708,4000 00For
Franklin Custodian Funds700,0000 00For
Jackson National678,4170 4,2360For
Allspring649,9050 00For
FRANKLIN STRATEGIC SERIES637,8080 00For
Equitable363,6180 267,0120For
AllianceBernstein00 574,1830Abstain
PRIMECAP Odyssey Funds479,0800 00For
TIAA446,0860 00For
Legg Mason442,5420 00For
MUTUAL FUND SERIES TRUST437,1300 00For

Showing the 25 largest of 123 asset managers. See all 123 in the interactive database.

5. To elect three (3) nominees for director, James C. Momtazee, Frank P. McCormick, Ph.D., and Hannah A. Valantine, M.D., to serve as Class I directors to hold office until the date of the annual meeting of stockholders following the year ending December 31, 2028 and until their successors are duly elected and qualified: Hannah A. Valantine, M.D.

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 9 wordings of this item as funds reported it.

80% Majority: yes · of votes cast

FOR 80%WITHHELD 20%
FOR: 129,081,930WITHHELD: 32,024,940

BridgeBio Pharma, Inc.’s own tally for this item (“Elect Director: Hannah A. Valantine, M.D.”): 129,081,930 for, 32,024,940 withheld, per its Form 8-K filed 2026-06-26 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 195,707,702 outstanding shares: 66% for, 16% withheld (82% of the company cast a for/withheld vote).

The 123 asset managers below cast 100% of the shares they voted on this item FOR (52,311,370 for, 0 against).

FOR 81%ABSTAIN 19%
FOR: 52,311,370 (81.0%)ABSTAIN: 12,263,497 (19.0%)NOT VOTED: 204 (0.0%)
Largest asset managers voting on “To elect three (3) nominees for director, James C. Momtazee, Frank P. McCormick, Ph.D., and Hannah A. Valantin” at BridgeBio Pharma, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard17,002,8210 72,4390For
Fidelity6,214,1850 60,1000For
BlackRock6,202,8580 00For
JANUS INVESTMENT FUND3,914,1050 1,389,6140For
Invesco3,054,1070 00For
T. Rowe Price2,714,0680 00For
Charles Schwab1,969,4100 4470For
Delaware/Macquarie00 1,134,6520Abstain
Columbia Threadneedle00 1,052,5230Abstain
Lord Abbett942,1450 00For
American Century00 831,1140Abstain
JPMorgan809,8540 00For
Capital Group763,7020 00For
Principal00 715,9390Abstain
Manager Directed Portfolios708,4000 00For
Franklin Custodian Funds700,0000 00For
Jackson National569,4730 113,1800For
Allspring00 649,9050Abstain
FRANKLIN STRATEGIC SERIES637,8080 00For
Equitable363,6180 267,0120For
AllianceBernstein00 574,1830Abstain
PRIMECAP Odyssey Funds479,0800 00For
TIAA446,0860 00For
Legg Mason436,5570 5,9850For
MUTUAL FUND SERIES TRUST437,1300 00For

Showing the 25 largest of 123 asset managers. See all 123 in the interactive database.

6. To elect three (3) nominees for director, James C. Momtazee, Frank P. McCormick, Ph.D., and Hannah A. Valantine, M.D., to serve as Class I directors to hold office until the date of the annual meeting of stockholders following the year ending December 31, 2028 and until their successors are duly elected and qualified: James C. Momtazee

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 9 wordings of this item as funds reported it.

97% Majority: yes · of votes cast

FOR 97%
FOR: 156,790,852WITHHELD: 4,316,018

BridgeBio Pharma, Inc.’s own tally for this item (“Elect Director: James C. Momtazee”): 156,790,852 for, 4,316,018 withheld, per its Form 8-K filed 2026-06-26 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 195,707,702 outstanding shares: 80% for, 2% withheld (82% of the company cast a for/withheld vote).

The 123 asset managers below cast 100% of the shares they voted on this item FOR (62,620,104 for, 0 against).

FOR 97%
FOR: 62,620,104 (97.0%)ABSTAIN: 1,954,762 (3.0%)NOT VOTED: 204 (0.0%)
Largest asset managers voting on “To elect three (3) nominees for director, James C. Momtazee, Frank P. McCormick, Ph.D., and Hannah A. Valantin” at BridgeBio Pharma, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard17,075,2480 130For
Fidelity6,274,2850 00For
BlackRock6,202,8580 00For
JANUS INVESTMENT FUND5,303,7190 00For
Invesco3,054,1070 00For
T. Rowe Price2,714,0680 00For
Charles Schwab1,969,8570 00For
Delaware/Macquarie1,134,6520 00For
Columbia Threadneedle1,052,5230 00For
Lord Abbett942,1450 00For
American Century831,1140 00For
JPMorgan809,8540 00For
Capital Group763,7020 00For
Principal458,2360 257,7030For
Manager Directed Portfolios708,4000 00For
Franklin Custodian Funds700,0000 00For
Jackson National678,4170 4,2360For
Allspring649,9050 00For
FRANKLIN STRATEGIC SERIES637,8080 00For
Equitable363,6180 267,0120For
AllianceBernstein00 574,1830Abstain
PRIMECAP Odyssey Funds479,0800 00For
TIAA446,0860 00For
Legg Mason442,5420 00For
MUTUAL FUND SERIES TRUST437,1300 00For

Showing the 25 largest of 123 asset managers. See all 123 in the interactive database.

7. To ratify the selection of Deloitte & Touche LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2026.

AUDIT-RELATED

99.9% fund support · no official result

FOR 99.9%

The 121 asset managers below cast 99.9% of the shares they voted on this item FOR (64,170,728 for, 4,275 against).

FOR: 64,170,728 (99.9%)AGAINST: 4,275 (0.0%)ABSTAIN: 40,809 (0.1%)NOT VOTED: 204 (0.0%)
Largest asset managers voting on “To ratify the selection of Deloitte & Touche LLP as the independent registered public accounting firm of the C” at BridgeBio Pharma, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard17,075,2610 00For
Fidelity6,274,2850 00For
BlackRock6,202,8580 00For
JANUS INVESTMENT FUND5,303,7190 00For
Invesco3,054,1070 00For
T. Rowe Price2,714,0680 00For
Charles Schwab1,969,8570 00For
Delaware/Macquarie1,134,6520 00For
Columbia Threadneedle1,052,5230 00For
Lord Abbett942,1450 00For
American Century831,1140 00For
JPMorgan809,8540 00For
Capital Group763,7020 00For
Principal715,9390 00For
Manager Directed Portfolios708,4000 00For
Franklin Custodian Funds700,0000 00For
Jackson National682,6530 00For
Allspring649,9050 00For
FRANKLIN STRATEGIC SERIES637,8080 00For
Equitable630,6300 00For
AllianceBernstein574,1830 00For
PRIMECAP Odyssey Funds479,0800 00For
TIAA446,0860 00For
Legg Mason442,5420 00For
MUTUAL FUND SERIES TRUST437,1300 00For

Showing the 25 largest of 121 asset managers. See all 121 in the interactive database.

8. Advisory Vote to Ratify Named Executive Officers' Compensation

SECTION 14A SAY-ON-PAY VOTES

61% fund support · no official result

FOR 61%AGAINST 39%

The 13 asset managers below cast 61% of the shares they voted on this item FOR (405,275 for, 255,472 against).

FOR: 405,275 (61.3%)AGAINST: 255,472 (38.7%)
Largest asset managers voting on “Advisory Vote to Ratify Named Executive Officers' Compensation” at BridgeBio Pharma, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Brighthouse0198,457 00Against
Erste Asset Management GmbH189,7250 00For
ALGERT GLOBAL LLC60,6800 00For
Granahan Investment Management, LLC60,6400 00For
Union Investment Management GmbH050,579 00Against
SECTOR GAMMA AS34,7590 00For
BlackRock22,4360 00For
CLEARWATER INVESTMENT TRUST17,6220 00For
Metzler Asset Management GmbH17,5060 00For
MIROVA06,436 00Against
FORUM FUNDS1,4250 00For
Empirical Financial Services, LLC d.b.a. Empirical Wealth Ma4740 00For
Milliman Funds Trust80 00For

9. Advisory Vote on Say on Pay Frequency

SECTION 14A SAY-ON-PAY VOTES

100% fund support · no official result

FOR 46.9%1 YEAR 49.7%

The 10 asset managers below cast 100% of the shares they voted on this item FOR (257,274 for, 0 against).

FOR: 257,274 (46.9%)1 YEAR: 272,801 (49.7%)ONE YEAR: 18,939 (3.4%)
Largest asset managers voting on “Advisory Vote on Say on Pay Frequency” at BridgeBio Pharma, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Brighthouse198,4570 00For
Erste Asset Management GmbH00 001 Year
Granahan Investment Management, LLC00 001 Year
SECTOR GAMMA AS34,7590 00For
BlackRock00 001 Year
CLEARWATER INVESTMENT TRUST17,6220 00For
Metzler Asset Management GmbH00 00One Year
MIROVA6,4360 00For
FORUM FUNDS00 00One Year
Milliman Funds Trust00 00One Year

10. Amend Omnibus Stock Plan

COMPENSATION

48.7% fund support · no official result

FOR 48.7%AGAINST 51.3%

The 5 asset managers below cast 48.7% of the shares they voted on this item FOR (198,457 for, 208,780 against).

FOR: 198,457 (48.7%)AGAINST: 208,780 (51.3%)
Largest asset managers voting on “Amend Omnibus Stock Plan” at BridgeBio Pharma, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Brighthouse198,4570 00For
Erste Asset Management GmbH0189,725 00Against
CLEARWATER INVESTMENT TRUST017,622 00Against
FORUM FUNDS01,425 00Against
Milliman Funds Trust08 00Against

11. Ratify Deloitte & Touche LLP as Auditors

AUDIT-RELATED

100% fund support · no official result

FOR 100%

The 5 asset managers below cast 100% of the shares they voted on this item FOR (407,237 for, 0 against).

FOR: 407,237 (100.0%)
Largest asset managers voting on “Ratify Deloitte & Touche LLP as Auditors” at BridgeBio Pharma, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Brighthouse198,4570 00For
Erste Asset Management GmbH189,7250 00For
CLEARWATER INVESTMENT TRUST17,6220 00For
FORUM FUNDS1,4250 00For
Milliman Funds Trust80 00For

12. Election of Directors

DIRECTOR ELECTIONS

All nominees (reported as one line). These filers reported the election of directors as a single line covering every nominee. It is not attributed to any one director, and no share total is shown for it.

100% fund support · no official result

FOR 100%

The 4 asset managers below cast 100% of the shares they voted on this item FOR.

FOR: 100.0%
Largest asset managers voting on “Election of Directors” at BridgeBio Pharma, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Advisors' Inner Circle Fund III43,1830 00For
Brighthouse7,9670 00For
McGowan Group Asset Management, Inc.1,0000 00For
Meeder Funds1530 00For

13. To conduct a non-binding advisory vote on the frequency of future non-binding advisory votes to approve the compensation of our NEOs.

SECTION 14A SAY-ON-PAY VOTES

Combines 2 wordings of this item as funds reported it.

— fund support · no official result

ONE YEAR 99.2%

No shares were cast for or against this item by the managers below — every disclosed position was an abstention or was not voted.

ONE YEAR: 176,376 (99.2%)NOT VOTED: 1,382 (0.8%)
Largest asset managers voting on “To conduct a non-binding advisory vote on the frequency of future non-binding advisory votes to approve the co” at BridgeBio Pharma, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Fiera Capital Corp00 00One Year
National Philanthropic Trust00 00Not Voted
STRATEGY ASSET MANAGERS LLC00 00One Year

14. 14A Executive Compensation

SECTION 14A SAY-ON-PAY VOTES

100% fund support · no official result

FOR 100%

The 2 asset managers below cast 100% of the shares they voted on this item FOR (1,009 for, 0 against).

FOR: 1,009 (100.0%)
Largest asset managers voting on “14A Executive Compensation” at BridgeBio Pharma, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
McGowan Group Asset Management, Inc.1,0000 00For
MQS Management LLC90 00For

15. 14A Executive Compensation Vote Frequency

SECTION 14A SAY-ON-PAY VOTES

— fund support · no official result

1 YEAR 100%

No shares were cast for or against this item by the managers below — every disclosed position was an abstention or was not voted.

1 YEAR: 1,000 (100.0%)
Largest asset managers voting on “14A Executive Compensation Vote Frequency” at BridgeBio Pharma, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
McGowan Group Asset Management, Inc.00 001 Year
MQS Management LLC00 00--

16. Amend Incentive Stock Option Plan

COMPENSATION

100% fund support · no official result

FOR 100%

The 2 asset managers below cast 100% of the shares they voted on this item FOR (4,250 for, 0 against).

FOR: 4,250 (100.0%)
Largest asset managers voting on “Amend Incentive Stock Option Plan” at BridgeBio Pharma, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
AMERICAN PENSION INVESTORS TRUST3,2500 00For
McGowan Group Asset Management, Inc.1,0000 00For

17. Ratify Appointment of Independent Auditors

AUDIT-RELATED

100% fund support · no official result

FOR 100%

The 2 asset managers below cast 100% of the shares they voted on this item FOR (4,250 for, 0 against).

FOR: 4,250 (100.0%)
Largest asset managers voting on “Ratify Appointment of Independent Auditors” at BridgeBio Pharma, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
AMERICAN PENSION INVESTORS TRUST3,2500 00For
McGowan Group Asset Management, Inc.1,0000 00For

18. SAY ON PAY

SECTION 14A SAY-ON-PAY VOTES

100% fund support · no official result

FOR 100%

The 2 asset managers below cast 100% of the shares they voted on this item FOR (10 for, 0 against).

FOR: 10 (100.0%)
Largest asset managers voting on “SAY ON PAY” at BridgeBio Pharma, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Empower100 00For
Ikarian Capital, LLC00 00--

19. To approve, on an advisory basis, the compensation of our named executive officers (“NEOs”), as disclosed in the Proxy Statement.

SECTION 14A SAY-ON-PAY VOTES

Combines 2 wordings of this item as funds reported it.

100% fund support · no official result

FOR 99.2%

The 2 asset managers below cast 100% of the shares they voted on this item FOR (176,326 for, 0 against).

FOR: 176,326 (99.2%)NOT VOTED: 1,382 (0.8%)
Largest asset managers voting on “To approve, on an advisory basis, the compensation of our named executive officers (“NEOs”), as disclosed in t” at BridgeBio Pharma, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Fiera Capital Corp176,3260 00For
National Philanthropic Trust00 00Not Voted

20. To approve, on an advisory basis, the compensation of our named executive officers, as disclosed in the Proxy Statement.

OTHER

Combines 2 wordings of this item as funds reported it.

100% fund support · no official result

FOR 100%

The 2 asset managers below cast 100% of the shares they voted on this item FOR (1,874,084 for, 0 against).

FOR: 1,874,084 (100.0%)
Largest asset managers voting on “To approve, on an advisory basis, the compensation of our named executive officers, as disclosed in the Proxy ” at BridgeBio Pharma, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
SC US (TTGP), LTD.1,874,0340 00For
STRATEGY ASSET MANAGERS LLC500 00For

Largest BridgeBio Pharma, Inc. shareholders voting in 2025-2026

Ranked by the number of BridgeBio Pharma, Inc. shares each manager voted on the most widely held ballot item of the 2025-2026 meeting, shown as a share of the 195,707,702 shares outstanding at the time of that meeting.

Top BridgeBio Pharma, Inc. shareholders by shares voted, 2025-2026
#Asset manager % of shares outstanding
1Vanguard 9.46%
2Janus Henderson 9.42%
3Kohlberg Kravis Roberts & Co. L.P. 6.78%
4VIKING GLOBAL INVESTORS LP 6.01%
5BlackRock 5.84%
6Fidelity 4.40%
7Invesco 3.66%
8T. Rowe Price 3.20%
9FARALLON CAPITAL MANAGEMENT, L.L.C. 2.93%
10JANUS INVESTMENT FUND 2.71%

Reported BridgeBio Pharma, Inc. ownership

Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).

BridgeBio Pharma, Inc. beneficial owners on record for the 2025-2026 proxy season
Holder % outstanding Disclosure
Vanguard Group 8.62% 13F
BlackRock 7.26% 13F
Ali J. Satvat 7.05% DEF14A
KKR Genetic Disorder L.P. 6.78% DEF14A
JANUS HENDERSON GROUP PLC 6.73% 13G
Viking Global Entities 6.05% DEF14A
VIKING GLOBAL INVESTORS LP 5.00% 13D
NEIL KUMAR 4.74% 13G
KKR Group Partnership L.P. 4.72% 13D
State Street 2.52% 13F

Percentages above are of 195,707,702 shares outstanding, as reported by BridgeBio Pharma, Inc. on its Form 10-Q dated 2026-03-31 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from BridgeBio Pharma, Inc.’s 10-Q dated 2026-03-31. This page is a static snapshot rebuilt weekly on 02 October 2026; a live search always shows the current data.

At BridgeBio Pharma, Inc.'s shareholder meeting held 2026-06-22, in the 2025-2026 proxy season, 466 asset managers reported how they voted in their SEC Form N-PX filings, covering 4,364 separate fund positions. Their filings are grouped here into 20 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. BridgeBio Pharma, Inc.'s own Form 8-K tally for this meeting is published below, but no row in it could be matched to the most widely held item, so this page states no certified outcome for that item. On that item — To approve, on an advisory basis, the compensation of the Company's named executive officers… — the reporting funds cast 94% of the shares they voted in favour (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). That is the aggregate of those managers' own N-PX disclosures, not the company's certified result, and the funds are a subset of all shareholders.

BridgeBio Pharma, Inc. proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).